<DOC>
	<DOC>NCT00357773</DOC>
	<brief_summary>To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety</brief_summary>
	<brief_title>Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis</brief_title>
	<detailed_description>The aim of the present study was to compare the efficacy and safety of T1225 1.5% eye drops administered BID for 3 days in comparison to reference antibiotic eye drops, tobramycin, for the treatment of purulent bacterial conjunctivitis. The study was conducted as a Phase III, multicentre, international, investigator-masked, randomised, parallel-group, non-inferiority study in newborns, children, and adults.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Bacterial</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Male or female &gt;= 1 day old (newborn, infant, child, adult); written informed consent by patient or legally acceptable representative; purulent bacterial conjunctivitis (unilateral or bilateral) defined as bulbar conjunctival injection (mild, moderate, or severe) AND conjunctival purulent discharge (mild, moderate or severe). Bacterial conjunctivitis diagnosed &gt;= 7 days ago; bacterial infection due to trauma or foreign body; dacryocystitis; corneal ulceration or keratitis; viral ocular infection; closed angle glaucoma; acute allergy conjunctivitis; clinically significant ocular abnormality; organic amblyopia, monophthalmia; corrected visual acuity below 20/100; contact lens wearer; newborn (i.e. 02 months old) not born at term (&lt; 37 weeks of amenorrhea); ocular surgery, laser in situ keratomileusis (LASIK), laser epithelial keratomileusis (LASEK), or photorefractive keratectomy (PRK) in last 12 months; ocular laser treatment in last 3 months; systemic macrolide antibiotics in last month; systemic steroids in last 2 weeks or during the study; topical ocular macrolide antibiotics and/or topical ocular steroids and/or nonsteroidal antiinflammatory drugs (NSAIDs) in last week; topical (ocular, nasal, bronchial etc.) treatments and/or systemic NSAIDs in last day; immunosuppressives and/or any systemic antibiotic on D0.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>